The study, which evaluates the investigational therapy ECUR-506, has demonstrated partial restoration of functional ornithine transcarbamylase (OTC) enzyme activity in the first patient dosed.

First participant dosed achieved complete clinical response per study protocol and data suggests partial restoration of functional OTC enzyme activity in the liver PHILADELPHIA--(BUSINESS WIRE ...

Quantumzyme Corporation (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is exploring innovative solutions in next-generation biocatalysis. By integrating AI-driven ...

Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is providing insight into the company's enzymatic design capabilities and current areas of ...

SAN DIEGO, CA - April 16, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is providing insight into the company’s enzymatic ...

“Our vision at Quantumzyme is to help reshape the future of industrial chemistry through the power of enzymatic catalysis,” stated Naveen Kulkarni, CEO of Quantumzyme. “By combining AI and ...